Protein that appears to play a key role in Alzheimer's disease

A protein that allows human cancer to resist multiple anticancer drugs also appears to play a key role in Alzheimer's disease, according to research conducted at Fox Chase Cancer Center. The protein, active in brain tissue, could be a target for new drugs to treat patients with Alzheimer's.

The report will appear in advance online publication the of the prestigious Federation of American Societies for Experimental Biology Journal ( on May 20, and will appear in the journal's July issue. The research was conducted in the Fox Chase laboratory of Kenneth D. Tew, Ph.D., D.Sc.

Tew's research has largely concentrated on understanding and circumventing mechanisms of cellular resistance to anticancer drugs and understanding cellular pathways that affect drug response and resistance. The new report concerns the human ABCA2 transporter, one of a large family of ATP-binding proteins that transport a variety of molecules across biological membranes.

ATP (adenosine triphosphate) is present in all living cells and serves as a major energy source for cellular reactions. Related transporter proteins with varying functions (there are over 50 coded for by the human genome) are widely expressed in human tissues according to Tew.

"The overexpression of the ABCA2 protein has been implicated in acquired resistance of tumors to the drug estramustine, which is used to treat prostate cancer patients," explained Tew, senior author of the paper. "This transporter is also expressed at high levels in brain tissue and may be linked with the transport of molecules relevant to the etiology of Alzheimer's disease, including those involved in the formation of amyloid plaques. The association of the transporter with Alzheimer's first emerged from a comparative gene expression pattern analysis that we did."

To analyze small changes in gene expression with little material, his laboratory developed Amplified Differential Gene Expression (ADGE) technology and ADGE microarray ("gene chip" technology for rapid analysis of gene expression) to examine cell lines made to express high levels ABCA2 protein. The microarray analysis revealed alterations in gene clusters related either to transport function or to oxidative stress response. This observation tied in with metabolism of free radicals and of beta-amyloid, a primary component of Alzheimer's disease plaques, consisting of dense deposits of protein and cellular material.

According to Tew, ABCA2 can play a role in cholesterol transport and also in myelination--an "insulation" for nerve cells in mammals and other vertebrates. Because these neurons are longer than other cells, they are more vulnerable to damage. Myelin protects them by sheathing their axons--threadlike extensions of the nerve cells--in alternating layers of protein and fat. A new model of human brain aging (Neurobiology of Aging, January 2003) postulates that mid-life breakdown of myelin could be a possible key to the later development of Alzheimer's disease.

"Imaging studies and examination of brain tissue have shown that the deterioration of myelin triggers the degeneration of complex neural connections," Tew said. "This may be due to genetic factors as well as the brain's own process of increasing cholesterol and iron levels in middle age.

"In samples of brain sections from Alzheimer's patients, the ABCA2 protein shows unusual patterns of expression," Tew added. "That also suggests that this transporter has a possible role in Alzheimer's."

Tew was chairman of pharmacology at Fox Chase until this May. He is now chairman of the Department of Cell and Molecular Pharmacology and Experimental Therapeutics at the Medical University of South Carolina in Charleston.

Tew's co-authors on the new FASEB Journal paper include technical specialist Zhijian J. Chen, postdoctoral fellow Bojana Vulevic, Ph.D., scientific technician Kristina Ile and postdoctoral associates Athena Soulika, Ph.D., and Warren Davis Jr., Ph.D., all of Fox Chase; Peter B. Reiner, Ph.D., Bruce P. Connop, Ph.D., and Parimal Nathwani, Ph.D., of Active Pass Pharmaceuticals Inc., in Vancouver, British Columbia; and John Q. Trojanowski, M.D., Ph.D., of the University of Pennsylvania's Center for Neurodegenerative Disease Research.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers reveal unique characteristics of previously unexplored protein FAM110A